Furthermore, both treatments increased the secretion of regulatory cytokines TGF-β and IL-10, but reduced the levels of the proinflammatory cytokines IL-17 and IL-6 in MSCs from SLE patients (Fig. 3K). This evidence concerns the gene IL17A and systemic lupus erythematosus.